NasdaqGM - Delayed Quote USD

TriSalus Life Sciences, Inc. (TLSIW)

1.1200

+0.0200

+(1.82%)

At close: January 30 at 4:00:00 PM EST

TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call

DENVER, January 23, 2025--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), is announcing preliminary unaudited fourth quarter and full year 2024 financial results and details of the upcoming conference call.

Business Wire 7 days ago

TLSI
+4.93%
TLSIW
+1.82%
TriSalus Life Sciences announces publication of pre-clinical data

TriSalus Life Sciences (TLSI) announced the publication of research titled, “Pressure Enabled Drug Delivery Significantly Increases Intraarterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Model,” in the peer-reviewed Journal of Vascular and Interventional Radiology. “This study further validates the potential of TriNav using the PEDD approach to transform the treatment of liver tumors. By significantly enhancing therapeutic delivery and sparing healthy tissue, PEDD offers a p

TipRanks 20 days ago

TLSI
+4.93%
TLSIW
+1.82%
TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System

DENVER, January 09, 2025--TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), TriSalus Life Sciences seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today the publication of research titled, "Pressure Enabled Drug Delivery (PEDD) Significantly Increases Intraarterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Mode

Business Wire 21 days ago

TLSI
+4.93%
TLSIW
+1.82%
TriSalus Announces Leadership Changes

DENVER, January 08, 2025--TriSalus announces leadership changes.

Business Wire 22 days ago

TLSI
+4.93%
TLSIW
+1.82%
TriSalus Reports Q3 2024 Financial Results and Provides Business Update

DENVER, November 14, 2024--TriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced its financial results for the third quarter ended September 30, 2024, and provided a business update.

Business Wire 2 months ago

TLSI
+4.93%
TLSIW
+1.82%
TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

DENVER, November 11, 2024--TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients suffering from liver cancer through its advanced delivery technology as well as an investigational immunotherapy, nelitolimod, has announced a strategic partnership with Geo-Med, LLC ("Geo-Med"), a certified Service-Disabled Veteran-Owned Small Business (SDVOSB), to expand availability of the TriNav Infusion System ("TriNav") to U.

Business Wire 2 months ago

TLSI
+4.93%
TLSIW
+1.82%
TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

DENVER, November 07, 2024--TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), a leader in oncology innovations integrating advanced delivery technology to transform treatment for liver and pancreatic tumors, today announced the launch of the TriNav® LV Infusion System and TriGuide™ Guiding Catheter. These new devices are designed to optimize therapeutic delivery, enhancing treatment options and potentially improving outcomes for patients.

Business Wire 2 months ago

TLSI
+4.93%
TLSIW
+1.82%
TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

DENVER, October 31, 2024--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, announced today it will host a conference call and webcast on November 14, 2024, at 9:00 a.m. ET to discuss financial results for the third quarter ended September 30, 2024, and provide a business update. A press release detailing the third quarter re

Business Wire 2 months ago

TLSI
+4.93%
TLSIW
+1.82%
TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

DENVER, October 14, 2024--TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, announced today that Mary Szela, Chief Executive Officer and President of TriSalus, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024.

Business Wire 3 months ago

TLSI
+4.93%
TLSIW
+1.82%
TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

DENVER, September 26, 2024--TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, has announced the addition of Riad Salem, M.D., to its Scientific Advisory Board (SAB).

Business Wire 4 months ago

TLSI
+4.93%
TLSIW
+1.82%
TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System

DENVER, September 23, 2024--TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with standard of care therapies and immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the publication of research titled, "Intra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model," in the peer-reviewed Jou

Business Wire 4 months ago

TLSI
+4.93%
TLSIW
+1.82%
TriSalus Life Sciences Inc (TLSI) CEO Buys Shares

Mary Szela, CEO and President of TriSalus Life Sciences Inc (NASDAQ:TLSI), purchased 14,815 shares of the company on September 13, 2024, according to a recent SEC Filing.

GuruFocus.com 4 months ago

TLSI
+4.93%
TLSIW
+1.82%
TriSalus Reports Q2 2024 Financial Results and Business Update

DENVER, August 15, 2024--TriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced its financial results for the second quarter ended June 30, 2024, and provided a business update.

Business Wire 5 months ago

TLSI
+4.93%
TLSIW
+1.82%
TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call

DENVER, August 01, 2024--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today it will host a conference call and webcast on August 15, 2024, at 9:00 a.m. ET to discuss financial results for the second quarter ended June 30, 2024, and provide a business update. A press release detailing the second quarter results will be issued prior to th

Business Wire 5 months ago

TLSI
+4.93%
TLSIW
+1.82%
TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation

WESTMINSTER, Colo., July 01, 2024--TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the closing of its previously announced exchange offer (the "Offer") and consent solicitation (the "Consent Solicitation") relating to its warrants (the "Warrants") identified in the Prospectus/Offer to Exchange that forms

Business Wire 6 months ago

TLSI
+4.93%
TLSIW
+1.82%
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants

WESTMINSTER, Colo., June 26, 2024--TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the expiration and results of its previously announced exchange offer (the "Offer") and consent solicitation (the "Consent Solicitation") relating to its warrants (the "Warrants") identified in the Prospectus/Offer to Excha

Business Wire 7 months ago

TLSI
+4.93%
TLSIW
+1.82%
TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting

DENVER, June 03, 2024--TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company integrating its novel Pressure Enabled Drug Delivery™ (PEDD™) technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced that data from its Phase 1b PERIO-02 clinical trial was presented in a poster session at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place May 31-June 4, 2024, in Chicago, Illinois.

Business Wire 7 months ago

TLSI
+4.93%
TLSIW
+1.82%
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants

DENVER, May 24, 2024--TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today that it has commenced an exchange offer (the "Offer") and consent solicitation (the "Consent Solicitation") relating to its warrants (the "Warrants") identified in the Prospectus/Offer to Exchange (as defined below). The purpose of the

Business Wire 8 months ago

TLSI
+4.93%
TLSIW
+1.82%
TriSalus Reports Q1 2024 Financial Results and Business Update

DENVER, May 15, 2024--TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the first quarter ended March 31, 2024, and provided a business update.

Business Wire 8 months ago

TLSI
+4.93%
TLSIW
+1.82%
TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors

DENVER, May 07, 2024--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the appointment of Liselotte Hyveled to its Board of Directors. Ms. Hyveled brings over two decades of experience stimulating scientific innovation and advancing pharmaceutical pipelines through research and development excellence.

Business Wire 8 months ago

TLSI
+4.93%
TLSIW
+1.82%

Performance Overview

Return	TLSIW	S&P 500
YTD	+0.90%	+2.78%
1-Year	+20.43%	+23.20%
3-Year	+136.29%	+36.99%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TriSalus Life Sciences, Inc. (TLSIW)

TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call

TriSalus Life Sciences announces publication of pre-clinical data

TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System

TriSalus Announces Leadership Changes

TriSalus Reports Q3 2024 Financial Results and Provides Business Update

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System

TriSalus Life Sciences Inc (TLSI) CEO Buys Shares

TriSalus Reports Q2 2024 Financial Results and Business Update

TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call

TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants

TriSalus Reports Q1 2024 Financial Results and Business Update

TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors

Performance Overview